The global non-alcoholic steatohepatitis (NASH) management market is undergoing strong expansion due to the rising prevalence of metabolic disorders, increasing awareness of liver diseases, and rapid advancements in diagnostics and therapeutic pipelines. NASH, a progressive form of non-alcoholic fatty liver disease (NAFLD), poses a significant risk of liver fibrosis, cirrhosis,...